{"id":5631,"date":"2024-01-12T08:55:34","date_gmt":"2024-01-12T14:55:34","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5631"},"modified":"2025-06-27T11:25:23","modified_gmt":"2025-06-27T16:25:23","slug":"nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la 20\u00aa Conferencia Anual de la Semana de Terapias Avanzadas"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>, TX \u2014 <span class=\"legendSpanClass\"><span class=\"xn-chron\">12 de enero de 2024<\/span><\/span>\u00a0 \u2014 <a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4066782-1&h=4060421553&u=https%3A%2F%2Fnanostherapeutics.com%2F&a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina, anunci\u00f3 hoy que el Dr.\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, Presidente y Director Cient\u00edfico, y Dr.\u00a0<span class=\"xn-person\">Jared Esteban<\/span>, El vicepresidente de estrategia y desarrollo comercial har\u00e1 una presentaci\u00f3n en el\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4066782-1&h=2177487416&u=https%3A%2F%2Fadvancedtherapiesweek.phacilitate.com%2Fwhy-advanced-therapies-week%2F&a=20th+Annual+Advanced+Therapies+Week+Conference\" target=\"_blank\" rel=\"nofollow noopener\">20a Conferencia Anual de la Semana de Terapias Avanzadas<\/a>\u00a0teniendo lugar desde\u00a0<span class=\"xn-chron\">16-19 de enero<\/span>\u00a0en el\u00a0<span class=\"xn-location\">miami<\/span>\u00a0Centro de Convenciones en\u00a0<span class=\"xn-location\">Miami, Florida<\/span>. Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n<p><b>T\u00edtulo:<\/b>\u00a0<b><u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4066782-1&h=1016285757&u=https%3A%2F%2Fadvancedtherapiesweek.phacilitate.com%2F2024-agenda%2F&a=Navigating+the+manufacturing+and+associated+regulatory+challenges+for+advancing+gene+therapies\" target=\"_blank\" rel=\"nofollow noopener\">Navegando por la fabricaci\u00f3n y los desaf\u00edos regulatorios asociados para avanzar en las terapias g\u00e9nicas<\/a><br class=\"dnr\" \/><\/u><\/b><b>T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Alineaci\u00f3n regulatoria y CMC para la fabricaci\u00f3n de terapias g\u00e9nicas<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">17 de enero de 2024<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">4:00 p.m. hora del este<\/span><br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>Teatro 2<br class=\"dnr\" \/><b>Presentador:\u00a0<\/b>Samarendra Mohanty, PhD, Presidente y Director Cient\u00edfico<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Mohanty:<\/p>\n<ul type=\"disc\">\n<li>Introducir la necesidad de estrategias con visi\u00f3n de futuro en la transici\u00f3n de procesos experimentales a procesos comercialmente viables.<\/li>\n<li>Cubrir el panorama regulatorio, los desaf\u00edos de los datos hist\u00f3ricos limitados y la comparabilidad de los lotes de fabricaci\u00f3n.<\/li>\n<li>Resaltar la importancia de la evaluaci\u00f3n de riesgos para justificar el enfoque anal\u00edtico y c\u00f3mo esto puede influir en la toma de decisiones.<\/li>\n<\/ul>\n<p><b>T\u00edtulo:<\/b>\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4066782-1&h=938445116&u=https%3A%2F%2Fadvancedtherapiesweek.phacilitate.com%2F2024-agenda%2F&a=Pioneering+a+New+Wave+of+Optogenetic+Therapeutics+for+Vision+Restoration%C2%A0\" target=\"_blank\" rel=\"nofollow noopener\"><b>Pioneros en una nueva ola de terapias optogen\u00e9ticas para la restauraci\u00f3n de la visi\u00f3n\u00a0<\/b><\/a><\/p>\n<p><b>T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0\u00a0Sesi\u00f3n destacada sobre terapia g\u00e9nica<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:<\/b>\u00a0<span class=\"xn-chron\">19 de enero de 2024<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:<\/b>\u00a010:00 am hora del este<br class=\"dnr\" \/><b>Ubicaci\u00f3n:<\/b>\u00a0Etapa de innovaci\u00f3n<br class=\"dnr\" \/><b>Presentador:<\/b>\u00a0Jared Stephens, PhD, vicepresidente de estrategia y desarrollo empresarial<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Stephens destacar\u00e1 los recientes avances cl\u00ednicos de los programas de Nanoscope basados en la l\u00ednea de productos de opsinas multicaracter\u00edsticas para la retinosis pigmentaria y la degeneraci\u00f3n macular de Stargardt.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen que restauran la visi\u00f3n para millones de pacientes ciegos por enfermedades retinianas hereditarias para las que no existe cura. El principal f\u00e1rmaco de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares de la fase RESTORE.\u00a0<span class=\"xn-money\">2b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinitis pigmentosa (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4066782-1&h=3842368197&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D4290035820%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3984630-1%2526h%253D517760235%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT04945772%25253Fterm%25253DNanoscope%252526draw%25253D2%2526a%253DNCT04945772%26a%3DNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4066782-1&h=3183015846&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D736901417%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3984630-1%2526h%253D1090222651%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT05417126%25253Fterm%25253Dnanoscope%252526draw%25253D2%252526rank%25253D3%2526a%253DNCT05417126%26a%3DNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u00a0). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS, TX \u2014 Jan. 12, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr.\u00a0Samarendra Mohanty, President &#038; Chief Scientific Officer, and Dr.\u00a0Jared Stephens, Vice President of Strategy &#038; Business Development will be presenting at the\u00a020th Annual Advanced Therapies Week Conference\u00a0taking place from\u00a0January 16-19\u00a0at the\u00a0Miami\u00a0Convention [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5633,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-12T14:55:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:25:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_Advanced-Therapies24.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference\",\"datePublished\":\"2024-01-12T14:55:34+00:00\",\"dateModified\":\"2025-06-27T16:25:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/\"},\"wordCount\":360,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_Advanced-Therapies24.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_Advanced-Therapies24.jpg\",\"datePublished\":\"2024-01-12T14:55:34+00:00\",\"dateModified\":\"2025-06-27T16:25:23+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_Advanced-Therapies24.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_Advanced-Therapies24.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/12\\\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 20.\u00aa Conferencia Anual de la Semana de Terapias Avanzadas - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-01-12T14:55:34+00:00","article_modified_time":"2025-06-27T16:25:23+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_Advanced-Therapies24.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference","datePublished":"2024-01-12T14:55:34+00:00","dateModified":"2025-06-27T16:25:23+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/"},"wordCount":360,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_Advanced-Therapies24.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/","url":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 20.\u00aa Conferencia Anual de la Semana de Terapias Avanzadas - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_Advanced-Therapies24.jpg","datePublished":"2024-01-12T14:55:34+00:00","dateModified":"2025-06-27T16:25:23+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_Advanced-Therapies24.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_Advanced-Therapies24.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/12\/nanoscope-therapeutics-to-present-at-the-20th-annual-advanced-therapies-week-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5631"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5631\/revisions"}],"predecessor-version":[{"id":9059,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5631\/revisions\/9059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5633"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}